

<b>Name</b>	: WERAGODA ARACHCHILAGE	<b>Age</b>	: 59 Years
<b>Referred By</b>	: Dr SUJEEWA SIYAMBALAPITIYA	<b>Gender</b>	: Female
<b>Sample ID</b>	: CTRN-2024-02516	<b>Reg Date</b>	: 06-Aug-2024 00:00:00
<b>MRD/MRN No.</b>	:	<b>Report Date</b>	: 12-Aug-2024 15:10:47

**HISTOPATHOLOGY**

**Immunohistochemistry**

**Lab no:** HLD/IHC-614-24

**Specimen**

Specimen type: Paraffin block no:SFH 290/24 A5  
 Specimen site: Right breast  
 Screening done by: Light microscopy

**Procedure**

IHC was performed by Automated Ventanna platform on the formalin fixed paraffin block.

**Interpretation**

Allred Score For Estrogen and Progesterone Receptor Evaluation

Markers	Positive cells		Intensity		Total score	Result
	Percentage	Score	Intensity	Score		
ER	95%	5	Strong	3	8	<b>Positive</b>
PgR	90%	5	Strong	3	8	<b>Positive</b>

**Her2 Testing by Immunohistochemistry**

Marker	Description(Criteria)	Score	Result
Her2	No staining observed	0	<b>Negative</b>

**Ki67 testing by immunohistochemistry**

Marker	Description(Criteria)	Score
Ki67	Positive in the invasive tumor.	25-28%

**Biomarker Summary**

Immunohistochemistry study shows:

ER positive and PR positive, but negative for HER2. Favouring Group 1 (luminal A) type- Invasive breast carcinoma.

\*\*Note: Luminal A breast cancers are likely to benefit from hormone therapy and may also benefit from chemotherapy.\*\*

Name	: WERAGODA ARACHCHILAGE	Age	: 59 Years
Referred By	: Dr SUJEEWA SIYAMBALAPITIYA	Gender	: Female
Sample ID	: CTRN-2024-02516	Reg Date	: 06-Aug-2024 00:00:00
MRD/MRN No.	:	Report Date	: 12-Aug-2024 15:10:47

## HISTOPATHOLOGY

### Method

**Fixative:** Formalin

**Markers used: Estrogen Receptor:** FDA approved antibody: DAKO, Primary antibody clone: EP1; **Progesterone Receptor:** FDA approved antibody: DAKO, Primary antibody clone: 636; **Her2(by immunohistochemistry):** FDA approved antibody: DAKO, Primary antibody clone: Polyclonal; **Ki67(by immunohistochemistry):** FDA approved antibody: DAKO, Primary antibody clone: MIB1

**Detection used:** Manual Detection system, Peroxidase/DAB

ASCO and Cap notes the following reasons for variability in test results


- Cold ischemia time and time of fixation.
- Type of fixative, if other than buffered formalin.
- Treatment of the tissue that could potentially alter immunoreactivity(e.g decalcification)
- Status of controls: Internal and external
- Adequacy of sample for evaluation.
- Primary antibody clone
- Regulatory status: FDA approved or laboratory tested.

**Reference:** Allred Scoring for ER and PgR receptors. ASCO/CAP guidelines.

### Note :

\* The results obtained relate only to the type of sample given/received at that time. A single test result is not always indicative of the disease. Histopathological specimens will be discarded after 1 month. Slides and paraffin blocks of histopathology & cytology will be stored for 5years.

### End of Report



**Dr. Apoorva N**

Consultant Pathologist  
MD Pathology, KMC114833



**Dr. Prabhu Meganathan**

Senior Consultant Pathologist  
MBBS, MD, KMC78087